A Study of BGM0504 in Healthy Participants and Participants With Impaired Renal Function

Prior treatment

• ● Allergic constitution includes severe drug allergy or history of drug allergy;
  • Have a personal or family history of medullary thyroid carcinoma or have multiple endocrine neoplasia syndrome type 2; Have a history or presence of pancreatitis;
  • Participants in clinical trials of any drug or medical device in the 3 months prior to screening;.
  • Suspected or confirmed history of alcohol or drug abuse;
  • Hepatitis B surface antigen (HBsAg), HIV antibody detection, hepatitis C virus antibody (HCVAb), treponema pallidum specific antibody detection, positive;
  • Donation or loss of 200 mL or more of blood within 3 months prior to screening, or blood donation during screening or within 1 months after the end of the trial;
  • Pregnant or Breast-feeding women;
  • The investigator considers that the participant has any other factors that would make it inappropriate to participate in this study.

• √ Age 18-65 years on the date of signing informed consent (inclusive);
  • Body mass index (BMI) within the range of 19.0-30.0 kg/m2 (inclusive);.
  • Stable renal function, assessed by two eGFR during screening (apart at least 3 days);
  • Diagnosed as stable, chronic renal disease for at least 3 months.
  • Renal function, assessed by estimated glomerular filtration rate at screening (eGFR):
  • Normal renal function: 90-129 mL/min (inclusive);
  • Mild impairment: 60-89 mL/min (inclusive);
  • Moderate impairment: 30-59 mL/min (inclusive);
  • Severe impairment: 15-29 mL/min (inclusive);